Abstract
Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.
Original language | English |
---|---|
Pages (from-to) | 11-30 |
Number of pages | 20 |
Journal | MCP : Molecular & cellular proteomics |
Volume | 19 |
Issue number | 1 |
Early online date | 7 Oct 2019 |
DOIs | |
Publication status | Published - 1 Jan 2020 |
Funding
This work was supported by: 1. Science Foundation Ireland Starting Investigator Research under Grant 13/SIRG/2164 to R.S.; 2. Swedish Research Council under Grant 8266 to G.L. and J.N.; 3. Alberta Glycomics Centre to C.C.; 4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under Grant K01- DK101632 to J.W.F.; 5. Australian Research Council Centre of Excellence for Nanoscale BioPhotonics (CNBP) under Grant CE1401000003 to N.H.P. and A.E.-D.; 6. European Union (EU) FP7 program HighGlycan under Grant 278535 to R.O.F. and P.M.R.; 7. National Institutes of Health (NIH) Research Resource for Biomedical Glycomics under Grant P41GM10349010 and Grant 1S10OD018530 to P.A.; 8. Austrian Research Promotion Agency Laura Bassi Center of Expertise under Grant 822757 to C.G.-G.; 9. National Natural Science Foundation of China under Grant 31600650, 31671369, and 31770775D to D.B., S.S., C.H. and Y.L.; 10. Deutsche Forschungs- gemeinschaft (DFG, German Research Foundation) "The concert of dolichol-based glycosylation: from molecules to disease models" under Grant FOR2509 to E.R.; 11. European Union (EC) "IMforFuture" under Grant 721815 to E.R.; 12. German Federal Ministry of Education and Research (BMBF) "Die Golgi Glykan Fabrik 2.0" under Grant 031A557 to S.C. and E.R.; 13. Health Canada, Government of Canada to T.D.C. and M.C.; 14. European Union FP7 GastricGlycoExplorer ITN under Grant 316929 and the Swedish Research Council under Grant 621-2013-5895 to N.G.K.; 15. National Research Council of Science and Technology Creative Allied Project (CAP) under Grant NTM2371511 to J.S.Y.; 16. Hungarian Government project under Grant NKFIH-K 116263 and BIONANO GINOP-2.3.2- 15-2016-00017 to A.G.; and 17. National Research Foundation of Korea under Grant NRF-2013M3A9B6075933 to H.J.A. * This work was supported by: 1. Science Foundation Ireland Starting Investigator Research under Grant 13/SIRG/2164 to R.S.; 2. Swedish Research Council under Grant 8266 to G.L. and J.N.; 3. Alberta Glycomics Centre to C.C.; 4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under Grant K01-DK101632 to J.W.F.; 5. Australian Research Council Centre of Excellence for Nanoscale BioPhotonics (CNBP) under Grant CE1401000003 to N.H.P. and A.E.-D.; 6. European Union (EU) FP7 program HighGlycan under Grant 278535 to R.O.F. and P.M.R.; 7. National Institutes of Health (NIH) Research Resource for Biomedical Glycomics under Grant P41GM10349010 and Grant 1S10OD018530 to P.A.; 8. Austrian Research Promotion Agency Laura Bassi Center of Expertise under Grant 822757 to C.G.-G.; 9. National Natural Science Foundation of China under Grant 31600650, 31671369, and 31770775D to D.B., S.S., C.H. and Y.L.; 10. Deutsche Forschungs- gemeinschaft (DFG, German Research Foundation) “The concert of dolichol-based glycosylation: from molecules to disease models” under Grant FOR2509 to E.R.; 11. European Union (EC) “IMforFuture” under Grant 721815 to E.R.; 12. German Federal Ministry of Education and Research (BMBF) “Die Golgi Glykan Fabrik 2.0” under Grant 031A557 to S.C. and E.R.; 13. Health Canada, Government of Canada to T.D.C. and M.C.; 14. European Union FP7 GastricGlycoExplorer ITN under Grant 316929 and the Swedish Research Council under Grant 621–2013-5895 to N.G.K.; 15. National Research Council of Science and Technology Creative Allied Project (CAP) under Grant NTM2371511 to J.S.Y.; 16. Hungarian Government project under Grant NKFIH-K 116263 and BIONANO GINOP-2.3.2-15–2016-00017 to A.G.; and 17. National Research Foundation of Korea under Grant NRF-2013M3A9B6075933 to H.J.A. □S This article contains supplemental Figures, Tables, and Discussion.
Funders | Funder number |
---|---|
FP7 GastricGlycoExplorer | 621–2013-5895 |
National Research Council of Science and Technology Creative Allied Project | |
National Institutes of Health | 822757, P41GM10349010 |
NIH Office of the Director | S10OD018530 |
National Institute of Diabetes and Digestive and Kidney Diseases | K01- DK101632 |
California Department of Fish and Game | |
Canadian Association of Palynologists | NTM2371511 |
Seventh Framework Programme | 721815, 278535, 316929 |
ARC Centre for Nanoscale BioPhotonics | CE1401000003 |
Health Canada | |
Government of Canada | |
European Commission | |
Deutsche Forschungsgemeinschaft | FOR2509 |
National Natural Science Foundation of China | 31671369, 31600650, 31770775D |
Bundesministerium für Bildung und Forschung | 031A557 |
Alberta Glycomics Centre | |
National Research Foundation of Korea | NRF-2013M3A9B6075933 |
Vetenskapsrådet | 8266 |
Keywords
- fluorescence
- glycan
- Glycomics
- glycopeptide
- glycoproteins
- glycosylation
- interlaboratory study
- mass spectrometry
- NISTmAb
- reference antibody